United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund Acquires 2,300 Shares of IDEXX Laboratories, Inc. $IDXX

Key Points

• United Super Pty Ltd increased its stake in IDEXX by 127.8% in Q3, buying 2,300 shares to hold 4,100 shares valued at about $2.62 million.
• Company insiders have been sizable sellers recently — CEO Jonathan Mazelsky sold 23,326 shares and EVP Nimrata Hunt sold 1,758, with insiders offloading 45,957 shares worth roughly $29.86 million in the last 90 days.
• IDEXX is a large-cap stock (market cap ≈ $48.4B) with a P/E of 46.6, FY2026 EPS guidance of 14.29–14.80, a consensus "Moderate Buy" and an average analyst price target of $783.33, trading in a 52-week range of $356.14–$769.98.

United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund lifted its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 127.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,100 shares of the company's stock after purchasing an additional 2,300 shares during the quarter. United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund's holdings in IDEXX Laboratories were worth $2,619,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. EverSource Wealth Advisors LLC grew its stake in IDEXX Laboratories by 2.5% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 621 shares of the company's stock worth $397,000 after buying an additional 15 shares in the last quarter. STF Management LP raised its position in shares of IDEXX Laboratories by 1.3% during the 2nd quarter. STF Management LP now owns 1,240 shares of the company's stock valued at $665,000 after buying an additional 16 shares in the last quarter. Clearstead Trust LLC lifted its holdings in shares of IDEXX Laboratories by 1.1% during the 2nd quarter. Clearstead Trust LLC now owns 1,515 shares of the company's stock worth $813,000 after acquiring an additional 16 shares during the last quarter. MassMutual Private Wealth & Trust FSB lifted its holdings in shares of IDEXX Laboratories by 4.4% during the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 380 shares of the company's stock worth $243,000 after acquiring an additional 16 shares during the last quarter. Finally, Moss Adams Wealth Advisors LLC grew its position in IDEXX Laboratories by 3.3% in the third quarter. Moss Adams Wealth Advisors LLC now owns 528 shares of the company's stock worth $337,000 after acquiring an additional 17 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors.

IDEXX Laboratories Price Performance

Shares of NASDAQ:IDXX opened at $608.41 on Friday. The company has a quick ratio of 0.90, a current ratio of 1.23 and a debt-to-equity ratio of 0.23. The stock has a market cap of $48.44 billion, a PE ratio of 46.55, a PEG ratio of 3.70 and a beta of 1.66. The company's fifty day moving average is $666.94 and its 200 day moving average is $668.42. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its quarterly earnings results on Monday, February 2nd. The company reported $2.92 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.93 by ($0.01). IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The business had revenue of $1.09 billion for the quarter, compared to analysts' expectations of $1.07 billion. During the same quarter in the previous year, the company earned $2.53 earnings per share. The business's quarterly revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Research analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Insider Buying and Selling

In related news, EVP Nimrata Hunt sold 1,758 shares of the stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $634.57, for a total transaction of $1,115,574.06. Following the completion of the sale, the executive vice president directly owned 18,141 shares in the company, valued at $11,511,734.37. This represents a 8.83% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Jonathan Jay Mazelsky sold 23,326 shares of the stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $657.55, for a total value of $15,338,011.30. Following the sale, the chief executive officer owned 83,606 shares of the company's stock, valued at $54,975,125.30. This represents a 21.81% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 45,957 shares of company stock worth $29,862,109 in the last 90 days. 0.98% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Barclays reduced their target price on IDEXX Laboratories from $850.00 to $800.00 and set an "overweight" rating on the stock in a research note on Thursday, February 5th. Weiss Ratings cut IDEXX Laboratories from a "buy (b-)" rating to a "hold (c+)" rating in a report on Thursday, January 29th. BTIG Research reduced their price objective on IDEXX Laboratories from $830.00 to $800.00 and set a "buy" rating on the stock in a research report on Tuesday, February 3rd. Piper Sandler decreased their price objective on IDEXX Laboratories from $775.00 to $750.00 and set a "neutral" rating on the stock in a report on Monday, February 9th. Finally, Wall Street Zen downgraded IDEXX Laboratories from a "strong-buy" rating to a "buy" rating in a research report on Saturday, February 28th. Seven analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $783.33.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.